公开(公告)号：US20190071452A1

公开(公告)日：2019-03-07

申请号：US16122116

申请日：2018-09-05

申请人： Eisai R&D Management Co., Ltd.

发明人： Yoshiaki Ohashi ,  Yoshihiko Norimine ,  Tamaki Hoshikawa ,  Yu Yoshida ,  Yoshihisa Kobayashi ,  Nobuhiro Sato ,  Koji Hagiwara

IPC分类号： C07D495/22 ,  A61P25/28 ,  A61P25/16

摘要： The present invention provides compounds represented by formulas (I) to (VI) or pharmaceutically acceptable salts thereof.

公开(公告)号：US11267821B2

公开(公告)日：2022-03-08

申请号：US16807335

申请日：2020-03-03

申请人： Eisai R&D Management Co., Ltd.

发明人： Yoshiaki Ohashi ,  Yoshihiko Norimine ,  Tamaki Hoshikawa ,  Yu Yoshida ,  Yoshihisa Kobayashi ,  Nobuhiro Sato ,  Koji Hagiwara ,  Nobuaki Sato ,  Shinsuke Hirota ,  Takaaki Harada ,  Hikaru Yoshimura

IPC分类号： C07D495/22 ,  A61K31/551 ,  A61P25/00 ,  C07D491/22 ,  C07D491/147

摘要： The present invention provides compounds represented by formulas (I) to (XVII) or pharmaceutically acceptable salts thereof:

公开(公告)号：US20130296352A1

公开(公告)日：2013-11-07

申请号：US13914898

申请日：2013-06-11

申请人： Eisai R&D Management Co., Ltd.

发明人： Yoshihiko Norimine ,  Kunitoshi Takeda ,  Koji Hagiwara ,  Yuichi Suzuki ,  Yuki Ishihara ,  Nobuaki Sato

IPC分类号： C07D471/04

CPC分类号： C07D471/04

摘要： A compound and/or pharmacologically acceptable salt thereof represented by the formula (I) has PDE9 inhibitory action, so that the intracerebral cGMP concentration is anticipated to be elevated. The PDE9 inhibitory action and the increase in cGMP lead to the improvement of learning and memory behaviors, and the compound (I) has applicability as a therapeutic agent for cognitive dysfunctions in Alzheimer's disease. wherein R1 is a hydrogen atom; R2 is an aromatic ring group, etc.; R3 is a hydrogen atom, etc; R4 is a hydrogen atom; R5 is an oxepanyl group, etc.; R6 is a hydrogen atom.

公开(公告)号：US20210255191A1

公开(公告)日：2021-08-19

申请号：US17163993

申请日：2021-02-01

申请人： Eisai R&D Management Co., Ltd. ,  SYSMEX CORPORATION

发明人： Daiki HARA ,  Takafumi Motoki ,  Yuji Kazuta ,  Yoshihiko Norimine ,  Hiroyuki Amino ,  Masatoshi Suganuma ,  Shingo Fujiyama ,  Kazuto Yamashita ,  Masaya Okada ,  Yoichi Nishikawa ,  Shigeki Iwanaga

IPC分类号： G01N33/58 ,  C09B57/00 ,  G01N21/64

摘要： Disclosed is: a fluorescent dye comprising a compound, a tautomer of the compound, or a salt of the compound or the tautomer; a labeled composite substance comprising the fluorescent dye and a composite substance which are bonded to each other; a composition containing the fluorescent dye or the labeled composite substance; and a method for acquiring information about a substance of interest by a super-resolution microscopy.

公开(公告)号：US10239889B1

公开(公告)日：2019-03-26

申请号：US16122116

申请日：2018-09-05

申请人： Eisai R&D Management Co., Ltd.

发明人： Yoshiaki Ohashi ,  Yoshihiko Norimine ,  Tamaki Hoshikawa ,  Yu Yoshida ,  Yoshihisa Kobayashi ,  Nobuhiro Sato ,  Koji Hagiwara

IPC分类号： A61K31/551 ,  A61P25/00 ,  C07D495/22 ,  A61P25/16 ,  A61P25/28

摘要： The present invention provides compounds represented by formulas (1) to (VI) or pharmaceutically acceptable salts thereof:

公开(公告)号：US09550776B2

公开(公告)日：2017-01-24

申请号：US14778202

申请日：2014-04-03

申请人： Eisai R&D Management Co., Ltd.

发明人： Yoshihiko Norimine ,  Nobuaki Sato ,  Yuki Ishihara ,  Kunitoshi Takeda

IPC分类号： A61K31/44 ,  C07D471/00 ,  C07D471/04 ,  A61K31/4745

CPC分类号： C07D471/04 ,  A61K31/4745

摘要： A compound represented by formula (I), or a pharmaceutically acceptable salt thereof: wherein R1 represents a group represented by the formula: a group represented by the formula: or a group represented by the formula: and R2 represents a 3-methyltetrahydro-2H-pyran-4-yl group or 4-methoxycyclohexyl group.

摘要翻译： 由式（I）表示的化合物或其药学上可接受的盐：其中R 1表示由下式表示的基团：由下式表示的基团或由下式表示的基团：R 2表示3-甲基四氢 -2H-吡喃-4-基或4-甲氧基环己基。

公开(公告)号：US11358972B2

公开(公告)日：2022-06-14

申请号：US16807335

申请日：2020-03-03

申请人： Eisai R&D Management Co., Ltd.

发明人： Yoshiaki Ohashi ,  Yoshihiko Norimine ,  Tamaki Hoshikawa ,  Yu Yoshida ,  Yoshihisa Kobayashi ,  Nobuhiro Sato ,  Koji Hagiwara ,  Nobuaki Sato ,  Shinsuke Hirota ,  Takaaki Harada ,  Hikaru Yoshimura

IPC分类号： C07D495/22 ,  A61K31/551 ,  A61P25/00 ,  C07D491/22 ,  C07D491/147

摘要： The present invention provides compounds represented by formulas (I) to (XVII) or pharmaceutically acceptable salts thereof:

公开(公告)号：US20200283452A1

公开(公告)日：2020-09-10

申请号：US16807335

申请日：2020-03-03

申请人： Eisai R&D Management Co., Ltd.

发明人： Yoshiaki Ohashi ,  Yoshihiko Norimine ,  Tamaki Hoshikawa ,  Yu Yoshida ,  Yoshihisa Kobayashi ,  Nobuhiro Sato ,  Koji Hagiwara ,  Nobuaki Sato ,  Shinsuke Hirota ,  Takaaki Harada ,  Hikaru Yoshimura

IPC分类号： C07D495/22 ,  C07D491/147 ,  C07D491/22

摘要： The present invention provides compounds represented by formulas (I) to (XVII) or pharmaceutically acceptable salts thereof:

公开(公告)号：US08563565B2

公开(公告)日：2013-10-22

申请号：US13644745

申请日：2012-10-04

申请人： Eisai R&D Management Co., Ltd.

发明人： Yoshihiko Norimine ,  Kunitoshi Takeda ,  Koji Hagiwara ,  Yuichi Suzuki ,  Yuki Ishihara ,  Nobuaki Sato

IPC分类号： A01N43/54 ,  A01N43/58 ,  A01N43/60 ,  A61K31/505 ,  A61K31/535 ,  C07D413/00 ,  C07D487/00 ,  C07D471/00 ,  C07D403/00

CPC分类号： C07D471/04

摘要： A compound and/or pharmacologically acceptable salt thereof represented by the formula (I) has PDE9 inhibitory action, so that the intracerebral cGMP concentration is anticipated to be elevated. The PDE9 inhibitory action and the increase in cGMP lead to the improvement of learning and memory behaviors, and the compound (I) has a potential use of a therapeutic agent for cognitive dysfunctions in Alzheimer's disease. wherein R1 is a hydrogen atom; R2 is an aromatic ring group, etc.; R3 is a hydrogen atom, etc; R4 is a hydrogen atom; R5 is an oxepanyl group, etc.; R6 is a hydrogen atom.

摘要翻译： 由式（I）表示的化合物和/或其药理学上可接受的盐具有PDE9抑制作用，从而预期脑内cGMP浓度升高。 PDE9抑制作用和cGMP的增加导致学习和记忆行为的改善，并且化合物（I）在阿尔茨海默病中具有治疗剂对认知功能障碍的潜在用途。 其中R1是氢原子; R2是芳环等; R3是氢原子等; R4是氢原子; R5是氧环丙烷基等。 R6是氢原子。

公开(公告)号：US20130143907A1

公开(公告)日：2013-06-06

申请号：US13644745

申请日：2012-10-04

申请人： Eisai R&D Management Co., Ltd.

发明人： Yoshihiko Norimine ,  Kunitoshi Takeda ,  Koji Hagiwara ,  Yuichi Suzuki ,  Yuki Ishihara ,  Nobuaki Sato

IPC分类号： C07D471/04

CPC分类号： C07D471/04

摘要： A compound and/or pharmacologically acceptable salt thereof represented by the formula (I) has PDE9 inhibitory action, so that the intracerebral cGMP concentration is anticipated to be elevated. The PDE9 inhibitory action and the increase in cGMP lead to the improvement of learning and memory behaviors, and the compound (I) has applicability as a therapeutic agent for cognitive dysfunctions in Alzheimer's disease. wherein R1 is a hydrogen atom; R2 is an aromatic ring group, etc.; R3 is a hydrogen atom, etc; R4 is a hydrogen atom; R5 is an oxepanyl group, etc.; R6 is a hydrogen atom.

摘要翻译： 由式（I）表示的化合物和/或其药理学上可接受的盐具有PDE9抑制作用，从而预期脑内cGMP浓度升高。 PDE9抑制作用和cGMP增加导致学习和记忆行为的改善，化合物（I）具有作为阿尔茨海默病认知功能障碍治疗剂的适用性。 其中R1是氢原子; R2是芳环等; R3是氢原子等; R4是氢原子; R5是氧环丙烷基等。 R6是氢原子。